MedTrace Logo

The Effect of Probiotics ATG-F4 in Cancer Patients

NCT06436976 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-05-31

No results posted yet for this study

Summary

Patients with advanced colorectal cancer or pancreatic cancer who are receiving oxaliplatin-based chemotherapy will be included. The research participants in this study will consume probiotics along with safety and anti-cancer agent side effect-related questionnaires, blood, and fecal sample collection for up to 12 weeks from the date of registration. The total duration of participation for research subjects is 12 weeks.

Conditions

Interventions

DRUG

LT-002 (Lactobacillus reuteri ATG-F4

The group that will be consuming probiotics for 12 weeks.

Sponsors & Collaborators

  • AtoGen Co. Ltd

    collaborator INDUSTRY

  • Chungnam National University Hospital

    lead OTHER

Principal Investigators

  • Hyewon Ryu, Professor · Department of Hematology Oncology

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06436976 on ClinicalTrials.gov